Fig. 2.

Inhibition of mitochondrial complex I with BAY 87-2243 blocks OXPHOS and triggers glycolysis in melanoma cells. a OCR was measured using Seahorse analyzer in BRAF mutant melanoma cells. BAY 87-2243 was injected (black arrow) in different concentrations (n = 6). b ECAR was measured using Seahorse analyzer in BRAF mutant melanoma cells. BAY 87-2243 was injected (black arrow) in different concentrations (n = 6). c Melanoma cells were treated with BAY 87-2243 (10 nM). Extracellular lactate was measured in cell culture supernatant after 8 h (n = 4). d OCR was measured using Seahorse analyzer in G-361 cells. BAY 87-2243 was injected (black arrow) in different concentrations followed by consecutive injections of oligomycin (1 μM), FCCP (0.5 μM), and antimycin A (1 μM)/rotenone (1 μM) (n = 6). e Melanoma cells were treated with different concentrations of BAY 87-2243. After 8 h, mitochondrial membrane potential was measured using Mito-ID assay (n = 3). CCCP (2 μM) was used as positive control. Data are represented as the mean ± SD. *p < 0.05